These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38594192)

  • 1. Atypia of undetermined significance and ThyroSeq v3-positive call rates as quality control metrics for cytology laboratory performance.
    Mejia-Mejia O; Bravo-Gonzalez A; Sanchez-Avila M; Tjendra Y; Santoscoy R; Drews-Elger K; Zuo Y; Arias-Abad C; Gomez C; Garcia-Buitrago M; Nadji M; Jorda M; Velez-Torres JM; Ruiz-Cordero R
    Cancer Cytopathol; 2024 Aug; 132(8):481-490. PubMed ID: 38594192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring the atypia of undetermined significance: Malignant ratio, ThyroSeq v3 positive call rate, molecular-derived risk of malignancy, and risk of malignancy as possible quality metric tools in thyroid cytology.
    Velez Torres JM; Curnow PM; Tjendra Y; Jorda M; Fernandez CG; Buitrago MG; Zuo Y; Cordero RR
    Cancer Cytopathol; 2024 Aug; 132(8):491-498. PubMed ID: 38594180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reproducibility of atypia of undetermined significance/follicular lesion of undetermined significance category using the bethesda system for reporting thyroid cytology when reviewing slides from different institutions: A study of interobserver variability among cytopathologists.
    Padmanabhan V; Marshall CB; Akdas Barkan G; Ghofrani M; Laser A; Tolgay Ocal I; David Sturgis C; Souers R; Kurtycz DF
    Diagn Cytopathol; 2017 May; 45(5):399-405. PubMed ID: 28217980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining molecular testing and the Bethesda category III:VI ratio for thyroid fine-needle aspirates: A quality-assurance metric for evaluating diagnostic performance in a cytopathology laboratory.
    Gokozan HN; Dilcher TL; Alperstein SA; Qiu Y; Mostyka M; Scognamiglio T; Solomon JP; Song W; Rennert H; Beg S; Stern E; Goyal A; Siddiqui MT; Heymann JJ
    Cancer Cytopathol; 2022 Apr; 130(4):259-274. PubMed ID: 34962713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ThyroSeq v3 for Bethesda III and IV: An institutional experience.
    Desai D; Lepe M; Baloch ZW; Mandel SJ
    Cancer Cytopathol; 2021 Feb; 129(2):164-170. PubMed ID: 33030808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular-derived risk of malignancy and the related positive call rate of indeterminate thyroid cytology diagnoses as quality metrics for individual cytopathologists.
    Ohori NP; Cuda JM; Bastacky SI; Yip L; Karslioglu-French E; Morariu EM; Ullal J; Ramonell KM; Carty SE; Nikiforov YE; Schoedel KE; Seethala RR
    Cancer Cytopathol; 2024 Feb; 132(2):109-118. PubMed ID: 37849056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benign call rate and molecular test result distribution of ThyroSeq v3.
    Ohori NP; Landau MS; Carty SE; Yip L; LeBeau SO; Manroa P; Seethala RR; Schoedel KE; Nikiforova MN; Nikiforov YE
    Cancer Cytopathol; 2019 Mar; 127(3):161-168. PubMed ID: 30561907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performance of repeat cytology with reflex ThyroSeq genomic classifier for indeterminant thyroid cytology.
    O'Conor CJ; Dash RC; Jones CK; Jiang XS
    Cancer Cytopathol; 2022 Jun; 130(6):469-476. PubMed ID: 35045202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation Between Histological Diagnosis and Mutational Panel Testing of Thyroid Nodules: A Two-Year Institutional Experience.
    Shrestha RT; Evasovich MR; Amin K; Radulescu A; Sanghvi TS; Nelson AC; Shahi M; Burmeister LA
    Thyroid; 2016 Aug; 26(8):1068-76. PubMed ID: 27283257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Probability of malignancy as determined by ThyroSeq v3 genomic classifier varies according to the subtype of atypia.
    Gajzer DC; Tjendra Y; Kerr DA; Algashaamy K; Zuo Y; Menendez SG; Jorda M; Garcia-Buitrago M; Gomez-Fernandez C; Velez Torres JM
    Cancer Cytopathol; 2022 Nov; 130(11):881-890. PubMed ID: 35775861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Qualifiers of atypia in the cytologic diagnosis of thyroid nodules are associated with different Afirma gene expression classifier results and clinical outcomes.
    Baca SC; Wong KS; Strickland KC; Heller HT; Kim MI; Barletta JA; Cibas ES; Krane JF; Marqusee E; Angell TE
    Cancer Cytopathol; 2017 May; 125(5):313-322. PubMed ID: 28152275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An institutional experience: A retrospective analysis of the effect of transitioning from follicular lesion of undetermined significance to atypia of undetermined significance with subclassified atypia on interobserver concordance, rates of neoplasia, and rates of malignancy.
    Kroll-Wheeler L; Cantley R; Pang JC; Soles BS; Smola B; Jing X; Lew M
    Diagn Cytopathol; 2021 Jan; 49(1):31-38. PubMed ID: 32936526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of the modification of the diagnostic criteria in the 2017 Bethesda System for Reporting Thyroid Cytopathology: a report of a single institution in Japan.
    Higuchi M; Hirokawa M; Kanematsu R; Tanaka A; Suzuki A; Yamao N; Hayashi T; Kuma S; Miyauchi A
    Endocr J; 2018 Dec; 65(12):1193-1198. PubMed ID: 30282887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of Malignancy and Risk of Neoplasia in the Bethesda Indeterminate Categories: Study on 4,532 Thyroid Fine-Needle Aspirations from a Single Institution in India.
    Mahajan S; Srinivasan R; Rajwanshi A; Radotra B; Panda N; Dey P; Gupta N; Nijhawan R
    Acta Cytol; 2017; 61(2):103-110. PubMed ID: 28407624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytological Diagnosis of Follicular Variant of Papillary Thyroid Carcinoma before and after the Bethesda System for Reporting Thyroid Cytopathology.
    Fazeli R; VandenBussche CJ; Bishop JA; Ali SZ
    Acta Cytol; 2016; 60(1):14-8. PubMed ID: 27007511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk stratification of cytologically indeterminate thyroid nodules with nondiagnostic or benign cytology on repeat FNA: Implications for molecular testing and surveillance.
    Hall EA; Hartzband P; VanderLaan PA; Nishino M
    Cancer Cytopathol; 2023 May; 131(5):313-324. PubMed ID: 36792948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thyroid cytology in Pakistan: An institutional audit of the atypia of undetermined significance/follicular lesion of undetermined significance category.
    Fatima S; Qureshi R; Imran S; Idrees R; Ahmad Z; Kayani N; Ahmed A
    Cytopathology; 2021 Mar; 32(2):205-210. PubMed ID: 33098589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular testing results as a quality metric for evaluating cytopathologists' utilization of the atypia of undetermined significance category for thyroid nodule fine-needle aspirations.
    VanderLaan PA; Nishino M
    J Am Soc Cytopathol; 2022; 11(2):67-73. PubMed ID: 34756586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of malignancy according to sub-classification of the atypia of undetermined significance or follicular lesion of undetermined significance (AUS/FLUS) category in the Bethesda system for reporting thyroid cytopathology.
    Kim SJ; Roh J; Baek JH; Hong SJ; Shong YK; Kim WB; Song DE
    Cytopathology; 2017 Feb; 28(1):65-73. PubMed ID: 27245883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of the 3rd Edition of the Bethesda System for Reporting Thyroid Cytopathology on Grey Zone Categories.
    Guerreiro SC; Tastekin E; Mourao M; Loureiro I; Eusebio R; Marques HP; Oznur M; Caliskan CK; Schmitt FC; Bongiovanni M; Canberk S
    Acta Cytol; 2023; 67(6):593-603. PubMed ID: 37899024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.